Press Releases

Promore Pharma publishes prospectus in connection with rights issue

Report from the Extraordinary Shareholders’ Meeting of Promore Pharma AB held on 22 October 2019

Promore Pharma engages ABG Sundal Collier as liquidity provider

Notice of Extraordinary Shareholders’ Meeting in Promore Pharma AB (publ)

Promore Pharma Promore Pharma carries out a rights issue of approximately SEK 75 million, underwritten up to 80 percent, and intends to publish its interim report early

Promore Pharma AB (publ) Interim report January – June 2019

Promore Pharma has recruited half of the patients in HEAL LL-37

Report from the Annual General Meeting of Promore Pharma AB held on 21 May 2019

Promore Pharma AB (publ) Interim report January – March 2019

Notice of Annual General Meeting in Promore Pharma AB (publ)

Promore Pharma AB (publ) Year-end report 2018

Promore Pharma modifies its Phase III trial of PXL01 and expands the number of clinics in the study

Promore Pharma AB (publ) Interim report January – September 2018

Promore Pharma receives approval for Phase III study with PXL01 in India

Promore Pharma has had a successful meeting with the FDA regarding PXL01

Promore Pharma has enrolled first patient in HEAL LL-37 in Poland

Promore Pharma receives approval for Phase IIb trial with LL-37 in Poland

Interim report January – June 2018

Promore Pharma receives approval for Phase IIb trial with LL-37

Report from the Annual General Meeting of Promore Pharma AB held on 16 May 2018

Promore Pharma AB (publ) Interim report January – March 2018

Promore Pharma Out-licenses PXL01 for Spinal Surgery to PharmaResearch Products Ltd

Promore Pharma 2017 Annual report published

Notice of Annual General Meeting in Promore Pharma AB (publ)

Promore Pharma Regains Rights for PXL01 Manufacturing

Year-end report 2017

Promore Pharma Adjusts Plans for PXL01 in North America

Interim report January – September 2017

Promore Pharma Signs Out-licensing Agreement with Transdermal Therapeutic Technologies for its Peptide DPK-060

Interim report January – June 2017